Hepatic KDM6B expression is substantially reduced in patients with NAFLD, and it participates in defective autophagy and hepatosteatosis (Byun et al. 2020), demonstrating its promising functional significance in the treatment of NAFLD. Here, KDM6B is linked to metabolic dysfunction-associated steatotic liver disease.